Pharmacy to Dose: The Critical Care Podcast

Christina Rose joins to highlight a July Trial of the Week “Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome” aka the ROSE trial, published in the New England Journal of Medicine in 2019.

We set the scene by reviewing the proposed mechanism of benefit with the use of neuromuscular blockers in severe ARDS. We highlight the ACURASYS trial, why its findings were semi-controversial, and differences in study design between ROSE and ACURASYS.

Then we dive into the Trial of the Week, discussing the study design and results. Were there any significant secondary outcomes or subgroup analyses? How did they monitor NMBA therapy? Is there a preferred NMBA? What do our current guidelines recommend? Have we officially answered the question of using NMBA in ARDS? Trial fun facts, how much does Christina love the ROSE trial, and much more!

If you enjoyed this episode, don’t miss the ARDS Part II episode that goes into detail on severe ARDS management in general: https://podcasts.apple.com/us/podcast/pharmacy-to-dose-the-critical-care-podcast/id1479298456?i=1000624172814